- Three-year cost-savings program through 2029 targeting $1.5 billion in annualized savings
AstraZeneca announced a three-year cost-savings program targeting $1.5 billion in annualized savings and reported Q3 earnings that beat expectations. The plan aims to reinvest in the drug pipeline and support the $80 billion revenue goal by 2030, sending shares up 7.4%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.